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A B S T R A C T
Purpose: Metabolic inhibition might sensitize tumors to irradiation. Here, we examined the effect of lonidamine
(several metabolic effects, inhibiting hexokinase amongst others) and/or 968 (glutaminase inhibitor) on tumor
cell metabolism, cell growth, cytotoxicity and radiosensitivity in NSCLC cell lines in vitro in relation to histology.
Materials and methods: Adeno- (H23, HCC827, H1975) and squamous cell carcinoma (H520, H292, SW900)
NSCLC cells were treated with lonidamine and/or 968 for 72 h under physiological levels of glucose (1.5mM).
Cells were irradiated with 0, 4 or 8 Gy. Cell growth of H2B-mCherry transduced cells and cytotoxicity (CellTox™
Green Cytotoxicity Assay) were measured using live cell imaging (IncuCyte). Inhibitory effects on metabolic
profiles was determined using the Seahorse XF96 extracellular Flux analyzer.
Results: NSCLC cell lines responded differently to glycolysis (lonidamine) and/or glutaminase (968) inhibition,
largely corresponding with changes in glycolytic and mitochondrial metabolism upon treatment. Response
patterns were not related to histology. 968 was cytotoxic in cell lines with high glutaminase C expression (H1975
and H520), whereas combination treatment was cytotoxic in KRAS mutated cell lines SW900 and H23. H292 and
HCC827 were resistant to combination treatment. Treatment with 968 and especially lonidamine resulted in
radiosensitization of H292 and HCC827 in terms of decreased relative cell growth and increased cytotoxicity.
Conclusion: NSCLC is a heterogeneous disease, which is reflected in the response of different cell lines to the
treatment (combinations) reported here. Only a part of NSCLC patients may benefit from the combination of
radiation therapy and metabolic inhibition, making stratification necessary.
1. Introduction
Standard treatment for irresectable stage III non-small cell lung
cancer (NSCLC) is concurrent/sequential chemoradiation. Despite this
intensive therapy, prognosis remains poor with 5-year survival of
13–36% [1]. Locoregional progression and distant metastases remain a
major issue [2]. Therefore, further intensification of treatment is re-
quired.
The metabolic switch from oxidative phosphorylation of pyruvate
towards glycolysis with production of lactate is involved in metastasis
formation, immune escape of tumor cells, angiogenesis and radio- and
chemoresistance [3–7]. Areas with residual 18F-fluorodeoxyglucose
(18F-FDG) uptake after radiotherapy correspond with the high 18F-FDG-
uptake regions pre-radiotherapy in NSCLC, indicating radioresistance
[8]. Glutamine metabolism of malignant cells contributes to the
synthesis of ATP, lipids, amino acids and nucleotides required for
proliferation, and to glutathione production for protection against
oxidative stress [9]. Essential for NSCLC growth in vitro is the gluta-
minase 1 (GLS1) splice variant glutaminase C (GAC), an enzyme that
catalyzes the hydrolysis of glutamine to glutamate, which is used in the
citric acid cycle of cancer cells as a source for anaplerosis [10]. In-
creased expression of the glutamine transporter SLC1A5 is a poor
prognostic factor in NSCLC [11]. Targeting SLC1A5 induces an increase
in intracellular reactive oxygen species (ROS) and apoptosis in SLC1A5-
high expressing NSCLC cell lines, and attenuates NSCLC tumor growth
in vivo [11,12]. Glutamine inhibition increases radiation-induced ROS
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and sensitizes pancreatic carcinoma to radiation in vitro and in an in vivo
mice study [13]. So, inhibiting glucose and/or glutamine metabolism
might optimize treatment for stage III NSCLC via depletion of energy
and macromolecules as well as sensitization to chemoradiation.
Emerging evidence supports differences in metabolism between
adeno- and squamous cell NSCLC, based on the expression of metabolic
transporters and enzymes, 18F-FDG-PET, and the level of metabolites.
Squamous cell carcinomas demonstrate an anaerobic (hypoxic) glyco-
lytic profile, i.e. poor vascularization, large necrotic areas, high lactate
level together with low glucose level and elevated expression of glucose
transporter 1 (GLUT1), combined with a glutaminolytic profile (in-
creased levels of glutamate and glutathione). Adenocarcinomas have a
better vascularization and likely oxygenation, and appear to have a
glycolytic metabolism under aerobic conditions [11,12,14–17]. Based
on these findings, it is of interest to exploit glucose and glutamine
metabolism in therapies allied to NSCLC histological subtypes.
Lonidamine (1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid)
is an agent with several effects on cell energy metabolism. It inhibits
glycolysis through interference with the function of mitochondrial-
bound hexokinase II, the enzyme that catalyzes the phosphorylation of
glucose into glucose-6-phosphate. Furthermore, it induces lactate ac-
cumulation and thereby intracellular acidification, and it inhibits the
formation of fumarate and malate. Finally, it disturbs the mitochondrial
transmembrane potential, decreases the oxygen consumption rate, in-
duces ROS through respiratory complex II (succinate dehydrogenase)
inhibition, and reduces levels of NADPH and glutathione in part by
inhibition of flux through the pentose phosphate pathway [18,19]. 968
(5-(3-Bromo-4-(dimethylamino)phenyl)-2,2-dimethyl-2,3,5,6-tetra-
hydrobenzo[a]phenanthridin-4(1H)-one) is an allosteric inhibitor,
which preferentially binds to and stabilizes the inactive, monomeric
state of GAC, thereby preventing it from undergoing conformational
changes to the active tetramer [20,21]. If GAC reaches an activated
state before 968 binding, then 968 is unable to inhibit enzyme activity.
So, protein turnover is required in order to prevent the activation of
GAC [20,21].
The aim of this study is to investigate the effect of treatment with
lonidamine and/or 968 on metabolism, tumor cell growth, cytotoxicity
and radiosensitivity in 6 NSCLC cell lines in vitro (3 adeno- and 3
squamous cell carcinoma) in relation to histology.
2. Materials and methods
2.1. Cell lines
Three adenocarcinomas (HCC827, H1975, H23) and three squa-
mous cell carcinomas (H292, SW900, H520) were used for the experi-
ments described below. Cell lines were authenticated by STR analysis.
H1975 and HCC827 harbor an EGFR mutation (H1975: c.2369C > T
(p.(Thr790Met)) (exon 20) and c.2573 T > G (p.(Leu858Arg) (exon
21); HCC827: c.2236_2250del (p.(Glu746_Ala750del)) (exon 19)). H23
and SW900 harbor a KRAS mutation. For live-cell imaging quantifica-
tion of cell numbers, cell lines were labeled with nuclear localized H2B-
mCherry by lentiviral transduction using a pLenti6.2/V5 DEST Gateway
vector (Invitrogen). Subsequently, cells were selected for blasticidin
resistance, and fluorescent cells were isolated by flow cytometry.
mCherry fluorescence signal diminished in H23 and H520, and could
therefore not be used to determine cell count in these cell lines. All
experiments were performed with RPMI medium (P04-17550, PAN-
Biotech GmbH, Aidenbach, Germany), supplemented with 10% (v/v)
fetal bovine serum, 1.5 mM D-glucose and 2mM L-glutamine, 20mM
Hepes, 1x non-essential amino acids, 20 U/ml penicillin, 20 ug/ml
streptomycin (all from Gibco). To mimic the tumor microenvironment,
we decided to use a physiological concentration of 1.5mM glucose
(unless otherwise specified). A higher non-physiological glucose con-
centration of 10mM results in a significant higher glucose consumption
and lactate production [22].
2.2. Glycolysis and mitochondrial metabolism by using Seahorse
Cells were seeded at an optimized cell density: 12.500 (H292),
20.000 (SW900), 25.000 (H1975 and HCC827) or 30.000 (H520 and
H23) cells/well and incubated the day after for 24 h with vehicle
(DMSO 0.075%), lonidamide (150 uM), 968 (10 uM) or a combination
of both. Metabolic profiles were generated using the Seahorse XF96
extracellular Flux analyzer (Seahorse Bioscience) as previously de-
scribed [23]. Baseline oxygen consumption rate (OCR) and extra-
cellular rate of acidification (ECAR) were determined after replacing
the growth medium with assay medium, containing the inhibitors or
vehicle (without serum), according to the manufacturer’s protocol [24].
A mitochondrial stress test was performed after subsequent injections of
oligomycin (1 uM; ATP synthase inhibitor), optimized FCCP (0.2 uM
for HCC827, 0.4 uM for H23 and 1 uM for the other cell lines) and a
mixture of rotenone and antimycin A (both 1 uM) (all from Sigma-Al-
drich) to measure changes in OCR for the evaluation of mitochondrial
ATP production, spare respiratory capacity and proton leak respec-
tively. A glycolysis stress test was performed to measure changes in
ECAR upon addition of glucose (10mM), optimized oligomycin (1 uM
for SW900 and H520, 2.5 uM for H23, HCC827 and H1975 and 5 uM
for H292) and 2-deoxyglucose (2-DG, 0.1M) (all from Sigma-Aldrich)
to evaluate glycolysis and glycolytic reserve. The addition of glucose
increases ECAR; this is reported as the rate of glycolysis under basal
conditions. Oligomycin inhibits mitochondrial ATP production, thereby
pushing cells to use glycolysis maximally. The subsequent increase in
ECAR is a parameter of the cellular maximum glycolytic capacity. Fi-
nally, 2-DG is added, a glucose analog that inhibits glycolysis through
competitive binding to hexokinase. The resulting decrease in ECAR
confirms that the ECAR produced in the experiment is due to glycolysis.
The difference between glycolytic capacity and glycolysis defines gly-
colytic reserve. The glycolytic reserve indicates how glycolytic a cell is,
i.e. a small glycolytic reserve means that the cells are more glycolytic.
Cellular respiration was corrected for total protein content, measured
using the Pierce BSA protein assay kit (Thermo Fisher).
2.3. Cell cycle
Cells were seeded at 10e6 cells/well, allowed to attach overnight
and afterwards incubated with inhibitors or vehicle as described above.
Cell Cycle distribution was assessed by flow cytometry (FACSCanto II,
BD Biosciences) after 30min incubation with 10 μg/ml PI, 100 μg/ml
RNAse A and 0.1% TritonX-100 in PBS. Histograms were analyzed
using FlowJo v10.0.8 (Tree Star) software and percentage cells in G0/
G1, S or G2/M-phase were calculated.
2.4. Real time PCR
Cells cultured in RPMI supplemented with 1.5mM D-glucose and
2mM L-glutamine were collected. Total RNA was isolated with the
Norgen’s Total RNA purification kit (Norgen Biotek Corp., Thorold,
Ontario, Canada), and RNA (0.5 μg) was reverse transcribed with the
iScript cDNA synthesis kit (Bio-Rad). qPCR was performed in triple with
specific primers for GLS1 (FW: 5′-AGGGTCTGTTACCTAGCTTGG-3′,
RV: 5′-ACGTTCGCAATCCTGTAGATTT-3′ and GAC (FW: 5′-GGTCTCC
TCCTCTGGATAAGATGG-3′, RV: 5′-GATGTCCTCATTTGACTCAGGT
GAC-3′) on a CFX96 real-time PCR detection system (Bio-Rad
Laboratories Inc, Richmond, CA) using SYBR Green. Levels are ex-
pressed as ratios of HPRT [25].
2.5. Cell growth and cytotoxicity
To assess the effect of metabolic inhibition on cell growth and cy-
totoxicity, cells were seeded in a 96-wells plate (#3596, Corning; 1
column for each condition) and exposed to: control-vehicle (DMSO
0.075%), 150 μM lonidamine (Sigma-Aldrich chemie) [19], 10 μM 968
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(Calbiochem) [26], combination treatment with lonidamine and 968.
Dose of lonidamine was based on the data of Guo et al. showing de-
creased level of the cellular antioxidants glutathione and NADPH upon
treatment with 150 μM lonidamine [19], and dose response experi-
ments demonstrating a decrease in confluence of about 50% for all six
cell lines after 72 h of treatment with 150 μM lonidamine (Supple-
mentary Data 1). Decreased amounts of reducing equivalents could
enhance the radiosensitivity of tumor cells and may therefore be im-
portant for radiation experiments [5]. For H292, H23, H1975 and
HCC827 4000 cells were seeded; 2000 cells for SW900 and 8000 for
H520. To settle, cells were left at room temperature for 20min.
Thereafter, plates were placed in the IncuCyte ZOOM Live-Cell Analysis
System (Essen BioScience) at 37 °C. Every 2 h, images were taken of
each well at 4x magnification for the entire experiment. When a con-
fluence of 20–25% (i.e. 20–25% of the well occupied by tumor cells;
bright-field images) was reached, cells were treated with lonidamine
and/or 968, or vehicle (control), and CellTox Green (1:4000, diluted in
RPMI without glucose and glutamine; Promega) was added to measure
cytotoxicity. Image processing was performed using Zoom2016 A soft-
ware (Essen BioScience). Images of red signal (mCherry), green signal
(CellTox) and confluence were binarized for further analysis. For seg-
mentation, thresholds were interactively set for cell lines individually at
intensities where the steepest gradient occurred between background
and foreground intensity levels. With these binary images, confluence,
mCherry count mm−2 and cytotoxicity count mm-2 were calculated.
Cytotoxicity index was calculated by cytotoxicity count mm−2/
mCherry count mm-2 (or confluence in case of unstable mCherry).
Correlation coefficients of mCherry count mm-2 and confluence were
0.997-0.999 for all control cell lines with stable mCherry.
2.6. Radiation experiments
The same amounts of cells as described above were seeded in a 96-
wells plate (#3596, Corning), and CellTox green was added. Six hours
after placing 96-wells plates in the IncuCyte, cells were treated with
lonidamine and/or 968. Twenty-four hours later, cells were irradiated
with 0 Gy (control), 4 Gy or 8 Gy (XRAD 320ix, PXI precision X-ray,
North Brandfod, CT). Confluence, mCherry count mm−2 and cytotoxi-
city count mm−2 were measured in pictures taken every 2 h at 4x
magnification, and analyzed as described above. This time point of
radiation was chosen based on the observation that mCherry and con-
fluence lines are separating relative to control for both compounds after
24 h of treatment, reflecting inhibitory efficacy (fourth panel of Fig. 1
and Supplementary Data 2). Data from irradiated conditions were
normalized to their non-irradiated counterpart to measure the radio-
sensitizing effect of metabolic inhibitors.
2.7. Statistics
Statistics were performed using Prism 4. Differences in glycolysis,
mitochondrial metabolism, cell growth and cytotoxicity between
treatment groups were assessed using Kruskal-Wallis test, followed by
Dunn’s post-hoc analyses. A p < 0.05 was considered statistically sig-
nificant.
3. Results
3.1. Metabolism in 6 NSCLC cell lines
Seahorse experiments (at 10mM glucose) showed that adenocarci-
noma cell lines (H23, HCC827, H1975) were more glycolytic relative to
squamous cell carcinoma cell lines (H520, H292, SW900) as their gly-
colytic reserve is smaller (p < 0.0001; Fig. 1, Supplementary Data 2,
upper panel), corresponding to earlier results of 18F-FDG-PET and tissue
analysis in patients which show glucose consumption under better
vascularized conditions in adenocarcinomas [14,15,17]. A similar
pattern, although with a lower glycolytic rate, was observed for ex-
periments with 1.5 mM glucose (Supplementary Data 3). H1975
showed the highest GLS1 and GAC mRNA levels (Fig. 2).
3.2. Effect of lonidamine and/or 968 on metabolism and cell cycle
In general, lonidamine decreased the glycolytic rate (significant for
H1975, p < 0.05) (Fig. 1, Supplementary Data 2, upper panel). Base-
line oxygen consumption rate (OCR) was significantly affected after
treatment in H520 (p= 0.045) and H1975 (p= 0.034). 968 attenuated
baseline OCR in H520 and especially H1975, corresponding with GAC
mRNA levels (Fig. 1 and 2, Supplementary Data 2, second panel). 968
remarkably decreased mitochondrial ATP production in H1975, H520,
HCC827 and H23. Combination treatment clearly decreased mi-
tochondrial ATP production in all cell lines (p < 0.05 for H520), ex-
cept in H292. Mitochondrial ATP production was fully blocked in
SW900 and H23. Other signs of inhibition of mitochondrial metabolism
are the decrease in spare respiratory capacity and increase in proton
leak, which are observed for monotherapy, and significantly for com-
bination therapy (spare respiratory capacity: H292: p < 0.05; proton
leak: H292, H520 and H1975: p < 0.01) (Fig. 1, Supplementary Data
2, third panel). Metabolic inhibition for 24 h did not affect cell cycle in
any of the cell lines (Supplementary Data 4).
3.3. Effect of lonidamine and/or 968 on cell growth and cytotoxicity
Decrease in cell growth after treatment with lonidamine correlated
partly with glycolytic rate as measured in Seahorse. HCC827 and
H1975, cell lines with the highest rate of glycolysis, showed a clear
response to lonidamine 72 h after treatment (43% and 53% cell growth
relative to control respectively). H292 and H520, cell lines with a lower
glycolytic profile, demonstrated less response to lonidamine (60% and
67% cell growth relative to control respectively). However, glycolytic
rate and response to lonidamine did not correlate for SW900 and H23
(Fig. 1, Supplementary Data 2, upper and fourth panel).
In the six cell lines, three patterns were observed after treatment
with lonidamine and/or 968: decrease in cell growth without cyto-
toxicity, cytotoxicity due to treatment with 968 only, and a severe cy-
totoxic effect of the combination treatment.
H292 and HCC827 demonstrate a decrease in cell growth after
(combination) treatment (p < 0.001 for both) without an increase in
cytotoxicity (Fig. 1, Supplementary Data 2, fourth and fifth panel).
Three days after (combination) treatment, cells remained viable (Fig. 3,
Supplementary Data 5). This corresponds with small changes in base-
line OCR and mitochondrial ATP production upon (combination)
treatment in H292 (Fig. 1, second and third panel).
Treatment with 968 was detrimental for the viability of H1975 cells
(Fig. 4); it increased cytotoxicity significantly (p < 0.05) (Fig. 1, fourth
and fifth panel). This corresponds with the high mRNA level of GAC in
H1975 (Fig. 2) and decrease in baseline OCR (Fig. 1, second panel).
Lonidamine decreased H1975 cell growth (p < 0.01) without a cyto-
toxic effect; combination treatment was very cytotoxic (p < 0.001)
(Fig. 1, fourth and fifth panel; Fig. 4). This pattern was also observed for
H520, although, to a lesser extent (Supplementary Data 2, fourth and
fifth panel; Supplementary Data 6).
Combination treatment was detrimental for cell growth and viabi-
lity in SW900 (p < 0.001 for both) and H23 (cell growth: p < 0.001;
cytotoxicity: p < 0.01) (Fig. 1, Supplementary Data 2, fourth and fifth
panel; Fig. 5, Supplementary Data 7). Cytotoxicity was significantly
increased after combination therapy in SW900 (p < 0.001), corre-
sponding to the drastic decrease in mitochondrial metabolism in this
cell line (full inhibition of mitochondrial ATP production, very high
proton leak, drastic decrease in OCR; Fig. 1, second and third panel).
This pattern was partly observed for H23 (total inhibition of mi-
tochondrial ATP production and a very high proton leak, but no de-
crease in OCR) (Supplementary Data 2, second and third panel).
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3.4. Radiosensitivity after metabolic inhibition
As combination therapy was very cytotoxic for most cell lines, effect
of combined metabolic inhibition on radiation response could not be
assessed under these circumstances. The same applies to the combina-
tion of 968 and radiation in H1975 and H520.
Two SCC cell lines (H292 and H520) were remarkably resistant to
radiation doses up to 8 Gy (decrease in cell growth of only 9–15% at
8 Gy relative to 0 Gy), while the other cell lines showed a decrease in
cell growth of 36–64% (Fig. 1, Supplementary Data 2, sixth panel).
Unfortunately, treatment with lonidamine or 968 did not sensitize the
H520 cell line to radiation (Supplementary Data 2, sixth panel). Inter-
estingly, the two cell lines that were resistant to (combination) meta-
bolic inhibitors, i.e. H292 and HCC827, did demonstrate a radio-
sensitizing effect upon treatment with 968 and especially with
lonidamine in terms of relative cell growth. Also, cytotoxicity index
increased substantially after treatment with lonidamine and irradiation
(Fig. 1, Supplementary Data 2, sixth and seventh panel; Supplementary
Data 8).
A summary of results is shown in Table 1.
4. Discussion
4.1. Different response to metabolic inhibitors in NSCLC cell lines
Earlier studies support a difference in metabolism between adeno-
and squamous cell NSCLC: squamous cell carcinomas demonstrate an
anaerobic (hypoxic) glycolytic profile combined with glutaminolysis,
while adenocarcinomas have a better vascularization/oxygenation and
seem to have a glycolytic metabolism under aerobic conditions
[11,12,14–17]. In this study, a varying response to metabolic inhibition
was observed across different NSCLC cell lines. However, this response
was not determined by histology, with both adeno- and squamous cell
carcinoma cell lines exhibiting different phenotypes. So, a generalized
metabolic inhibition approach for NSCLC seems not to be possible and
predictive markers are required for selection of treatment.
Combination treatment of lonidamine and 968 was detrimental for
cell growth and viability in the two KRAS-mutated cell lines (SW900
and H23). Monotherapy decreased cell growth, but did not affect cy-
totoxicity. Likely, these cell lines are able to compensate for blocking of
only one of these metabolic routes. For example, glutaminolysis in the
citric acid cycle can be increased upon treatment with lonidamine [19].
Furthermore, the mitochondrial isoform of phosphoenolpyruvate car-
boxykinase (PCK2) is expressed and active in NSCLC, including H23
[27,28]. PCK2 expression and activity are enhanced under low-glucose
conditions. Under limited availability of glucose, PCK2 converts glu-
tamine-derived oxaloacetate into the glycolytic intermediate phos-
phoenolpyruvate (PEP). Glutamine-derived PEP is used to fuel biosyn-
thetic pathways normally sustained by glucose through
gluconeogenesis (i.e. the opposite direction of glycolysis), thereby re-
plenishing other glycolytic intermediates. These can be used in a
number of biosynthetic processes, such as serine and glycerol synthesis,
nucleotide synthesis and NADPH generation via the pentose phosphate
pathway [27,28]. Also uptake of lactate may serve as a gluconeogenic
Fig. 1. Effect of metabolic inhibition on glycolysis, mitochondrial metabolism, cell growth and cytotoxicity, and radiosensitivity for H292, H1975 and SW900.
Upper panel: Effect of 968 and/or lonidamine on glycolytic rate as assessed by extracellular acidification rate (ECAR). Cell lines are cultured in RPMI medium with
10mM glucose. Bars represent mean value.
Second panel: Effect of 968 and/or lonidamine on baseline oxygen consumption rate (OCR). Cell lines are cultured in RPMI medium with 4.5 g/l glucose. Bars
represent mean value.
Third panel: Effect of 968 and/or lonidamine on mitochondrial ATP production, spare respiratory capacity and proton leak. Cell lines are cultured in RPMI medium
with 4.5 g/l glucose. Bars represent mean value.
Fourth panel: Effect of 968 and/or lonidamine on cell growth (mCherry count
(mm−2)) up to three days after treatment.
Fifth panel: Effect of 968 and/or lonidamine on cytotoxicity up to three days after treatment.
Sixth panel: Radiosensitizing effect (in terms of mCherry count) of metabolic inhibition three days after radiation. Irradiated control data are normalized relative to
control 0 Gy, irradiated 968 data are normalized relative to 968 0 Gy etc. to measure the radiosensitizing effect of metabolic inhibitors.
Seventh panel: Radiosensitizing effect (in terms of cytotoxicity index) of metabolic inhibition three days after radiation. Irradiated control data are normalized
relative to control 0 Gy, irradiated 968 data are normalized relative to 968 0 Gy etc. to measure the radiosensitizing effect of metabolic inhibitors.
Fig. 2. mRNA levels of glutaminase in 6 NSCLC cell lines.
GLS1 mRNA level
GAC mRNA level
Cell lines are cultured in RPMI medium with 1.5 mM glucose and 2mM glutamine.
Abbreviations:GACglutaminase C; GLS1: glutaminase 1. mRNA levels are expressed as ratios of HPRT.
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precursor through PCK2 activity [27]. In this way, PCK2 activity helps
to adapt to low-glucose conditions and enables glucose-independent
cell proliferation. PCK2 inhibition leads to a significant increase in
glucose depletion-induced apoptosis in H23 and A549 cells (both KRAS
mutated) but not in H1299 cells (KRAS wildtype). Under high-glucose
conditions (20mM), PCK2 inhibition has no effect in H23 and H549
[27]. In oncogenic KRAS- or BRAF-driven NSCLC cells, autophagy
provides an intracellular glutamine supply to sustain mitochondrial
Fig. 3. Cell growth and cytotoxicity after metabolic inhibition in H292.
Microscopic images three days after metabolic inhibition for control-vehicle, 968, lonidamine and combination treatment. Magnification 4× . Scale bar represents
400 μm. Red: mCherry, green: cytotoxicity.
Fig. 4. Cell growth and cytotoxicity after metabolic inhibition in H1975.
Microscopic images three days after metabolic inhibition for control-vehicle, 968, lonidamine and combination treatment. Magnification 4× . Scale bar represents
400 μm. Red: mCherry, green: cytotoxicity.
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function [29]. Moreover, reprogramming of glutamine metabolism
mediated by oncogenic KRAS in pancreatic ductal adenocarcinoma cells
results in the conversion of glutamine-derived aspartate into pyruvate
through malic enzyme 1 with the production of NADPH for maintaining
redox homeostasis [30,31]. RAS-driven cancer cells display aerobic
glycolysis and glutamine can provide carbon for anaplerosis in these
cells [9,32,33]. So, KRAS mutation might be a predictive marker for
response to combination inhibition of glycolysis and glutamine meta-
bolism.
NSCLC cell lines show a variable range of glutamine dependency
[10]. Glutaminase inhibition by 968 was cytotoxic for cell lines with
high GAC mRNA level (H1975 and H520). Therefore, GAC expression
could be a predictive marker for response to 968 monotherapy. H292
and HCC827 demonstrated a decrease in cell growth after (combina-
tion) treatment without an increase in cytotoxicity. Apparently, these
cell lines are able to compensate for this (combination) therapy. Re-
markably, H292 showed only a small decrease in baseline OCR and had
the highest mitochondrial ATP production after combination treatment
(Fig. 1, second and third panel; Fig. 3), possibly due to metabolism of
other fuels like lipids and lactate instead of glucose and glutamine
[34–36]. Recently, it was demonstrated that lactate-derived carbons are
detected in citric acid cycle intermediates in tumors derived from
HCC827 cell line [35]. Furthermore, HCC827 and H292 showed a
substantial increase in basal respiration when exposed to glucose-free
medium containing fatty acids relative to medium containing glucose,
while this increase was not observed for H1975 (preliminary un-
published data). This observation further strengthens our hypothesis
that H292 and HCC827 cells are able to survive inhibition of glucose
and glutamine metabolism by fueling fatty acids in mitochondrial re-
spiration.
Goodwin et al. performed glycolysis inhibition experiments in
adeno- (A549 and H522) and squamous cell (HCC95 and HCC1588)
NSCLC cell lines by using GLUT1 knockdown, 2-deoxyglucose and
WZB117 (a selective, small-molecule GLUT1 inhibitor) [37]. GLUT1
knockdown decreased glucose uptake, markedly suppressed the pro-
liferative capacity of the squamous cell carcinoma cell lines HCC95 and
HCC1588, accompanied by extensive apoptosis and cell death, and
lower amount of intracellular ATP and NAD(P)H. GLUT1 knockdown
also decreased glucose uptake in adenocarcinoma cell lines A549 and
H522. In contrast to squamous cell carcinoma cell lines, these adeno-
carcinoma cell lines showed only moderately suppressed proliferation
upon GLUT1 knockdown without induction of apoptosis or cell death
and no changes in intracellular amount of ATP [37]. GLUT1 knockdown
significantly inhibited in vivo growth of HCC95 tumors, but did not
affect in vivo growth of H549 and H522 tumors. Squamous cell carci-
noma cell lines HCC95 and HCC1588 were more apoptotic upon
treatment with 2-deoxyglucose or WZB117 compared to A549 and
H522 adenocarcinoma cell lines, despite similar decrease in glucose
Fig. 5. Cell growth and cytotoxicity after metabolic inhibition in SW900.
Microscopic images three days after metabolic inhibition for control-vehicle, 968, lonidamine and combination treatment. Magnification 4× . Scale bar represents
400 μm. Red: mCherry, green: cytotoxicity.
Table 1
Summary of results.
Adenocarcinomas Squamous cell carcinomas
H23 HCC827 H1975 H520 H292 SW900
GAC mRNA + + +++ ++ + +
KRAS mutation Yes No No No No Yes
Growth reduction
Lonidamine + ++ ++ + ++ ++
968 + + + + + +
Combination +++ +++ +++ ++ +++ +++
Cytotoxicity
Lonidamine – – – – – +
968 – – + + – –
Combination ++ – ++ ++ – +++
Radiosensitizing
effect
Lonidamine – ++ – – ++ –
968 – + – – + –
Cytotoxicity after
radiation
Lonidamine – + – – + –
968 – – – – – –
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uptake and extracellular acidification rate. 2-Deoxyglycose-treated or
WZB117-treated HCC1588 squamous cell carcinoma tumors exhibited
significant in vivo tumor growth reduction, with no anti-tumor activity
in treated A549 adenocarcinomas [37].
This selective cytotoxicity of glycolysis inhibition in squamous cell
carcinomas observed by Goodwin et al. suggests a specific reliance on
glucose metabolism in squamous cell carcinomas and metabolic com-
pensatory mechanism to maintain bioenergetics, cellular viability and
proliferative capacity in adenocarcinomas. We also found metabolic
flexibility among NSCLC cell lines, but we could not support this his-
tology-based difference in our in vitro experiments, possibly due to the
fact that lonidamine has multiple effects on metabolism apart from
glycolysis inhibition. Furthermore, heterogeneity is likely to exist
within these histological subtypes. For example, the A549 adenocarci-
noma cell line was more sensitive to GLUT1 knockdown compared to
H522 adenocarcinoma cell line, in agreement with higher GLUT1
mRNA and protein expression in A549. Moreover, in adenocarcinoma
patient tumors, predominantly micropapillary and solid adenocarci-
nomas exhibit higher GLUT1 expression and 18F-FDG-uptake compared
to adenocarcinomas with a predominantly lepidic, acinar or papillary
growth pattern [38,39], further supporting heterogeneity among sub-
classifications. Heterogeneity might also exist among squamous cell
carcinoma cell lines, as the HCC2450 squamous cell carcinoma tumor
line exhibits much lower GLUT1 mRNA and protein compared to the
examined HCC1588 and HCC95 cell lines. Unfortunately, HCC2450 was
not exposed to GLUT1 knockdown, 2-deoxyglucose or WZB117 in the
study by Goodwin et al [37].
An interesting observation in our study is the increase in proton leak
for both compounds, but especially for combination treatment in all cell
lines. Proton leak gives an indication about the leakage of protons out
of the mitochondrial space. Oxidative phosphorylation runs according
to the following principles: i) Electrons of the tricarboxylic acid cycle
donate their energy in a series of redox reactions, in which oxygen is
reduced into water; ii) This energy is used to create a proton gradient;
iii) This proton gradient drives ATP synthesis. So, compounds dis-
turbing the mitochondrial transmembrane structure or potential could
influence proton leak. Lonidamine is known to disturb the mitochon-
drial transmembrane potential [18], and thus is likely to influence
proton leak. For 968, this effect has not been described.
4.2. Metabolic inhibition and response to radiation in NSCLC
Lonidamine and 968 demonstrated a radiosensitizing effect in H292
and HCC827. Sappington et al. observed that BPTES, a GLS-1 specific
inhibitor, reduced cell viability and proliferation and substantially re-
duced extracellular glutathione excretion in H460 and H549 cells. GLS-
1 inhibition markedly resulted in a radiosensitizing effect in these cell
lines, suggesting the importance of glutamine-derived glutathione in
redox control and radioresistance [40]. A key metabolic role of onco-
genic KRAS is to maintain redox balance, by regulating metabolism of
glutamine amongst others [41]. Glutamine deprivation sensitized the
KRAS mutated NSCLC cell line HCC44 to radiation, but not the KRAS
wildtype H522 [30]. We could not confirm the radiosensitizing effect of
glutamine inhibition in KRAS mutated cell lines. The effect of gluta-
minase inhibition on the redox status (higher ROS, and decrease in
glutathione and NADPH) and radiosensitivity has also been observed
for cervical and pancreatic cancer cells [13,42]. Also lonidamine in-
duces ROS formation and inhibits NADPH and glutathione generation
[19]. However, in four NSCLC cell lines, we did not observe a radio-
sensitizing effect of metabolic inhibitors. Conversely, metabolic in-
hibition resulted in radioresistance in H1975, SW900, H23 an H292.
We hypothesized that metabolic inhibition resulted in cell cycle arrest
due to depletion of energy and macromolecules, as arrest in G0/G1
phase causes radioresistance, but we were unable to confirm this hy-
pothesis. Han et al. showed that 968 inhibited NSCLC cell proliferation
and arrested G0/G1 phase of cell cycle in A549 and H23 [43]. These
different observations between studies might be due to the hetero-
geneity of NSCLC cell lines and differences in experimental set-up, like
glucose concentration and time of treatment with metabolic inhibitor.
Furthermore, 968 and combined treatment could be too cytotoxic to be
able to demonstrate a radiosensitizing effect in H1975, SW900, H23
and H292 (Fig. 4–5, Supplementary Data 6–7). A lower compound dose,
probably resulting in less cytotoxicity, may increase the radiation ef-
fect.
The diversity in response of NSCLC cell lines to the combination of
metabolic inhibition and radiation therapy may explain the negative
result of the prospective randomized comparison of radiation therapy
plus lonidamine versus radiation therapy alone for nonresectable NSCLC
[44]. A trend towards better local control was observed for patients
treated with lonidamine and radiation, which suggests that only a part
of patients benefit from treatment with lonidamine, underlining the
need to better select patients for such treatment modifications [44].
Thus, a general approach regarding metabolic inhibition to improve
radiotherapy efficacy is not possible for NSCLC and predictive markers
are required.
4.3. Translation of in vitro results into in vivo
The tumor microenvironment can affect cancer cell metabolism
[34]. For this reason, we mimicked the tumor microenvironment by
using a more physiological concentration of 1.5 mM glucose [22].
Glucose concentrations vary within tumors, and many tumors have
average levels between 1 and 2mM. However, other nutrients like
glutamine are also in excess in standard culture medium and might also
have an impact on our results. Furthermore, in standard culture con-
ditions, oxygen is abundant (21%), while oxygen levels in even the best
perfused tissues are 9% or less and can be very low in tumors [34]. As
oxygen level influences metabolism [45], this could have an impact on
the response to metabolic inhibitors in vivo. Moreover, human NSCLC
tumors demonstrate metabolically heterogeneous regions within tu-
mors related to the degree of perfusion [46]. All together, this implies
that the tumor microenvironment, including tumor vasculature sup-
plying nutrients and oxygen, influences the metabolic phenotype of
cancer cells and sensitivity to metabolic inhibitors.
4.4. Conclusion
NSCLC is a heterogeneous set of diseases. Cell lines responded dif-
ferently to glycolysis and/or glutaminase inhibition, largely corre-
sponding with changes in glycolytic and mitochondrial metabolism
upon treatment, but response patterns were not related to histological
subtype. Interestingly, response patterns were associated with KRAS
mutation status and level of GAC expression. The glutaminase inhibitor
968 decreased cell growth and was cytotoxic in cell lines with high GAC
expression (H1975 and H520), whereas combination treatment was
detrimental for cell growth and viability in the KRAS mutated cell lines
(SW900 and H23). Two of six cell lines (H292 and HCC827) were quite
resistant to combination treatment and may depend on or switch to
other fuels like phospholipids and lactate. 968 and especially lonida-
mine were able to radiosensitize the H292 and HCC827 NSCLC cell
lines. Therefore, only a part of NSCLC patients may benefit from the
combination of radiation therapy and metabolic inhibition, making
stratification and predictive markers necessary. As the tumor micro-
environment affects the metabolic phenotype of tumor cells, these ob-
servations should be confirmed in in vivo models and patients.
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